Lead Product(s) : Anamorelin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Oberland Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Helsinn Closes Financing Agreement with Oberland Capital
Details : Adlumiz (anamorelin) is a selective, novel, orally active ghrelin receptor agonist. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism.
Brand Name : Adlumiz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 10, 2023
Lead Product(s) : Anamorelin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Oberland Capital Management
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
